Prevention of COVID-19 by mRNA-based vaccines within the general population of California
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background: Estimates of COVID-19 vaccine effectiveness under real-world conditions, and understanding of barriers to uptake, are necessary to inform vaccine rollout. Methods: We enrolled cases (testing positive) and controls (testing negative) from among the population whose SARS-CoV-2 molecular diagnostic test results from 24 February-29 April 2021 were reported to the California Department of Public Health. Participants were matched on age, sex, and geographic region. We assessed participants’ self-reported history of COVID-19 vaccine receipt (BNT162b2 and mRNA-1273). Participants were considered fully vaccinated two weeks after second dose receipt. Among unvaccinated participants, we assessed willingness to receive vaccination, when eligible. We measured vaccine effectiveness (VE) via the matched odds ratio of prior vaccination, comparing cases with controls. Results: We enrolled 1023 eligible participants aged ≥18 years. Among 525 cases, 71 (13.5%) received BNT162b2 or mRNA-1273; 20 (3.8%) were fully vaccinated with either product. Among 498 controls, 185 (37.1%) received BNT162b2 or mRNA-1273; 86 (16.3%) were fully vaccinated with either product. Two weeks after second dose receipt, VE was 86.8% (95% confidence interval: 68.6-94.7%) and 85.6% (69.1-93.9%) for BNT162b2 and mRNA-1273, respectively. Fully vaccinated participants receiving either product experienced 91.3% (79.7-96.3%) and 68.3% (28.5-86.0%) VE against symptomatic and asymptomatic infection, respectively. Among unvaccinated participants, 42.4% (159/375) residing in rural regions and 23.8% (67/281) residing in urban regions reported hesitancy to receive COVID-19 vaccination. Conclusions: Authorized mRNA vaccines are effective at reducing documented SARS-CoV-2 infections within the general population of California. Vaccine hesitancy presents a barrier to reaching coverage levels needed for herd immunity. Brief points: Vaccination is preventing documented SARS-CoV-2 infection in California, with 68% and 91% effectiveness against asymptomatic and symptomatic infection, respectively. Vaccine effectiveness was equivalent for BNT126b2 and mRNA-1273. Only 66% of unvaccinated participants were willing to receive the vaccine when eligible.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
Research works printed but not linked: 15
- Sadoff J , Le Gars M , Shukarev G , et al. Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med 2021; :NEJMoa2034201. · DOI · Paper page
- 2020, Postlicensure Evaluation of COVID-19 Vaccines, JAMA, 324, 1939, 10.1001/jama.2020.19328 · DOI · Paper page
- Lewnard JA , Patel MM , Jewell NP , et al. Theoretical framework for retrospective studies of the effectiveness of SARS-CoV-2 vaccines. Epidemiology, 2021. Available at: http://medrxiv.org/lookup/doi/10.1101/2021.01.21.21250258. Accessed 1 May 2021. · doi:10.1101/2021.01.21.21250258
- 2021, Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients, The Lancet, 397, 875, 10.1016/S0140-6736(21)00448-7 · DOI · Paper page
- 2021, Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021, MMWR Morb Mortal Wkly Rep, 70, 495, 10.15585/mmwr.mm7013e3 · DOI · Paper page
- Honaker J , King G , Blackwell M. Amelia II: A Program for Missing Data. J Stat Soft 2011; 45. Available at: http://www.jstatsoft.org/v45/i07/. Accessed 2 September 2020. · DOI · Paper page
- 2020, Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated?, Vaccine, 38, 6500, 10.1016/j.vaccine.2020.08.043 · DOI · Paper page
- 2021, COVID-19 Vaccination Hesitancy in the United States: A Rapid National Assessment, J Community Health, 46, 270, 10.1007/s10900-020-00958-x · DOI · Paper page
- 2021, COVID-19 and vaccine hesitancy: A longitudinal study, PLOS ONE, 16, e0250123, 10.1371/journal.pone.0250123 · DOI · Paper page
- McCabe SD , Hammershaimb EA , Cheng D , et al. Unraveling Attributes of COVID-19 Vaccine Hesitancy in the U.S.: A Large Nationwide Study. medRxiv 2021; :2021.04.05.21254918. · DOI
- Momplaisir F , Haynes N , Nkwihoreze H , Nelson M , Werner RM , Jemmott J. Understanding Drivers of Coronavirus Disease 2019 Vaccine Hesitancy Among Blacks. Clinical Infectious Diseases 2021; Available at: https://doi.org/10.1093/cid/ciab102. Accessed 1 May 2021. · DOI · Paper page
- 10.1016/j.vaccine.2016.10.042 · DOI · Paper page
- Grumbach K , Judson T , Desai M , et al. Association of Race/Ethnicity With Likeliness of COVID-19 Vaccine Uptake Among Health Workers and the General Population in the San Francisco Bay Area. JAMA Intern Med 2021; Available at: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2778176. Accessed 1 May 2021. · doi:10.1001/jamainternmed.2021.1445
- 2021, Trends in Health Care Worker Intentions to Receive a COVID-19 Vaccine and Reasons for Hesitancy, JAMA Netw Open, 4, e215344, 10.1001/jamanetworkopen.2021.5344 · DOI
- 10.1093/aje/kwy163 · DOI · Paper page
Cited by
Fiolet, T., Kherabi, Y., MacDonald, C.-J., Ghosn, J., & Peiffer-Smadja, N. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.005 · Cited by 911
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
Sadarangani, M., Marchant, A., & Kollmann, T. R. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00578-z · Cited by 560
Mohammed, I., Nauman, A., Paul, P., Ganesan, S., Chen, K.-H., Jalil, S. M. S., Jaouni, S. H., Kawas, H., Khan, W. A., Vattoth, A. L., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2027160 · Cited by 406
Lewnard, J. A., Hong, V. X., Patel, M. M., Kahn, R., Lipsitch, M., & Tartof, S. Y. (2022) · Nature Medicine · doi:10.1038/s41591-022-01887-z · Cited by 390
Self-citationRanzani, O. T., Hitchings, M. D. T., Dorion, M., D’Agostini, T. L., de Paula, R. C., de Paula, O. F. P., Villela, E. F. D. M., Torres, M. S. S., de Oliveira, S. B., Schulz, W., et al. (2021) · BMJ · doi:10.1136/bmj.n2015 · Cited by 348
Metadata
- Authors
- Andrejko, K. L., Pry, J., Myers, J. F., Jewell, N. P., Openshaw, J., Watt, J., Jain, S., & Lewnard, J. A.
- Venue
- medRxiv
- Publisher
- openRxiv
- Published
- 2021-04-10
- OpenAlex
- W3153006927
- Cited by
- 43
- References
- 3
- Type
- posted content
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevention of COVID-19 by mRNA-based vaccines within the general population of California. https://app.cochat.ai/papers/10.1101/2021.04.08.21255135
- The paper
- Andrejko, K. L., Pry, J., Myers, J. F., Jewell, N. P., Openshaw, J., Watt, J., Jain, S., & Lewnard, J. A. (2021). Prevention of COVID-19 by mRNA-based vaccines within the general population of California. medRxiv. https://doi.org/10.1101/2021.04.08.21255135
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.